Bitcoin’s success reflects a growing shift in how the world approaches not only cryptocurrency but also financial markets as ...

RBI's big beautiful monetary policy, rising market activity a cause for concern, global growth slows but markets are soaring, ...

Axsome Therapeutics (AXSM) shares drop after FDA declines review of fibromyalgia treatment AXS-14. Read more here.

How Rick Carter, producer designer of blockbusters for Steven Spielberg and Jim Cameron, sees GenAI emerging as a ...

Axsome Therapeutics received a refusal-to-file letter from the Food and Drug Administration for its new drug application for its fibromyalgia drug AXS-14.

Vineeth Gogineni is a Manager at Bain & Company, based in the Dallas office, serving private and public sector clients across ...

AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia ...

Shares of Axsome Therapeutics, Inc. (AXSM) slumped 3% in the pre-market session on Monday after the company said that it has ...

THE Government should have employed a more diplomatic approach through back channels in addressing Venezuela’s claims of ...

Ecological stability requires a systems–based framework promoting joint responsibility for the future of humanity. The Fourth ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...